Why BioNTech, Moderna, and Novavax Stocks Soared This Week

Motley Fool2021-07-23

What happened Shares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week. The common denominator driving all ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

willnlol
2021-07-26
willnlol
End end
KLok
2021-07-24
KLok
Better luck next week.....
Jazzc85
2021-07-23
Jazzc85
They soar as the cases soar..
Atwosome
2021-07-23
Atwosome
Good sharing
- Sunshine88:
  Like and comment
- Atwosome:
  ok
DonaldL
2021-07-23
DonaldL
Ok
- Atwosome:
  ok
raredom
2021-07-23
raredom
Like and comment
- thuiminn:
  like and comment
- trashbin:
  Ok
- Chibichibi:
  Ok

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2153198394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-23 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2153198394","market":"us","top_or_hot":-1,"title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","media":"Motley Fool","content":"<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","article_id":"2153198394","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","pubTimestamp":1627034820,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Concerns about the delta variant are rising.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","AZNCF":"AstraZeneca Plc","NVAX":"诺瓦瓦克斯医药"},"translate_title":"为什么生物技术公司、莫德纳公司和诺瓦瓦克斯医药公司的股票本周飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNCF":0.9,"BNTX":0.9,"MRNA":0.9,"NVAX":0.9,"PFE":0.9},"content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":800882520,"gmtCreate":1627290990160,"gmtModify":1703486891507,"author":{"id":"3578871663749183","authorId":"3578871663749183","name":"willnlol","avatar":"https://static.tigerbbs.com/208844269ff22e7e65d50d6a8f09c6d1","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":1,"authorIdStr":"3578871663749183","idStr":"3578871663749183"},"htmlText":"End end","listText":"End end","text":"End end","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/800882520","repostId":2153198394,"repostType":2,"repost":{"id":"2153198394","pubTimestamp":1627034820,"share":"https://ttm.financial/m/news/2153198394?lang=&edition=fundamental","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":174483389,"gmtCreate":1627126156941,"gmtModify":1703484588192,"author":{"id":"3582450584533032","authorId":"3582450584533032","name":"KLok","avatar":"https://static.tigerbbs.com/7d135114c7d99f91051322404730d3e0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3582450584533032","idStr":"3582450584533032"},"htmlText":"Better luck next week.....","listText":"Better luck next week.....","text":"Better luck next week.....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/174483389","repostId":2153198394,"repostType":2,"repost":{"id":"2153198394","pubTimestamp":1627034820,"share":"https://ttm.financial/m/news/2153198394?lang=&edition=fundamental","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":175579421,"gmtCreate":1627044335863,"gmtModify":1703483109367,"author":{"id":"3581583688503326","authorId":"3581583688503326","name":"Jazzc85","avatar":"https://community-static.tradeup.com/news/b4945b6e44a944760efcbe15223e98d5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581583688503326","idStr":"3581583688503326"},"htmlText":"They soar as the cases soar..","listText":"They soar as the cases soar..","text":"They soar as the cases soar..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175579421","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","pubTimestamp":1627034820,"share":"https://ttm.financial/m/news/2153198394?lang=&edition=fundamental","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":175505183,"gmtCreate":1627039363142,"gmtModify":1703482987902,"author":{"id":"3571305152732730","authorId":"3571305152732730","name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":8,"crmLevelSwitch":1,"authorIdStr":"3571305152732730","idStr":"3571305152732730"},"htmlText":"Good sharing","listText":"Good sharing","text":"Good sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/175505183","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","pubTimestamp":1627034820,"share":"https://ttm.financial/m/news/2153198394?lang=&edition=fundamental","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5312632,"gmtCreate":1627086399521,"gmtModify":1663231410029,"authorId":3586140387931872,"author":{"id":3586140387931872,"idStr":"3586140387931872","authorId":3586140387931872,"name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175505183,"type":1,"supId":5305579,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"},{"id":5305579,"gmtCreate":1627039371228,"gmtModify":1663231376239,"authorId":3571305152732730,"author":{"id":3571305152732730,"idStr":"3571305152732730","authorId":3571305152732730,"name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.31","exceedPercentage":"93.09%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175505183,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":175276984,"gmtCreate":1627038574848,"gmtModify":1703482970923,"author":{"id":"3566684989982146","authorId":"3566684989982146","name":"DonaldL","avatar":"https://static.tigerbbs.com/5d913d97919adf9f7d3c525aa1cc3a9c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3566684989982146","idStr":"3566684989982146"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/175276984","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","pubTimestamp":1627034820,"share":"https://ttm.financial/m/news/2153198394?lang=&edition=fundamental","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5305580,"gmtCreate":1627039380173,"gmtModify":1663231376750,"authorId":3571305152732730,"author":{"id":3571305152732730,"idStr":"3571305152732730","authorId":3571305152732730,"name":"Atwosome","avatar":"https://static.tigerbbs.com/2085a92415ef32924f70d916d490adce","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.31","exceedPercentage":"93.09%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175276984,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":175227861,"gmtCreate":1627036570153,"gmtModify":1703482933583,"author":{"id":"3581768035538210","authorId":"3581768035538210","name":"raredom","avatar":"https://static.tigerbbs.com/77737b5631b06cd6b34c3ca4f2e7ca21","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3581768035538210","idStr":"3581768035538210"},"htmlText":"Like and comment&nbsp;","listText":"Like and comment&nbsp;","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/175227861","repostId":2153198394,"repostType":4,"repost":{"id":"2153198394","pubTimestamp":1627034820,"share":"https://ttm.financial/m/news/2153198394?lang=&edition=fundamental","pubTime":"2021-07-23 18:07","market":"us","language":"en","title":"Why BioNTech, Moderna, and Novavax Stocks Soared This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2153198394","media":"Motley Fool","summary":"Concerns about the delta variant are rising.","content":"<h2><b>What happened</b></h2>\n<p>Shares of <b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> soared 21.3% this week as of the market close on Thursday. <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> and <b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> stocks also both jumped 12.4% this week.</p>\n<p>The common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.</p>\n<p>There was also other news driving a couple of the stocks higher. BioNTech and its partner, <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>,&nbsp;announced&nbsp;a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.</p>\n<p><img src=\"https://static.tigerbbs.com/b257aa87b3da956f9b55806df62948e3\" tg-width=\"700\" tg-height=\"463\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2><b>So what</b></h2>\n<p>Although worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.</p>\n<p>One study published in the <i>New England Journal of Medicine</i> on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and <b><a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a></b>'s vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.</p>\n<p>However, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.</p>\n<p>How the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.</p>\n<h2><b>Now what</b></h2>\n<p>Look for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.</p>\n<p>For Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why BioNTech, Moderna, and Novavax Stocks Soared This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy BioNTech, Moderna, and Novavax Stocks Soared This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","AZNCF":"AstraZeneca Plc","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/07/23/why-biontech-moderna-and-novavax-stocks-soared-thi/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153198394","content_text":"What happened\nShares of BioNTech SE soared 21.3% this week as of the market close on Thursday. Moderna, Inc. and Novavax stocks also both jumped 12.4% this week.\nThe common denominator driving all three vaccine stocks higher was increased concern about the delta variant of the coronavirus. COVID-19 cases in the U.S. and several other countries across the world are rising due to the highly contagious strain. The Centers for Disease Control and Prevention (CDC) said earlier this week that the delta variant now accounts for 83% of new COVID-19 cases in the U.S.\nThere was also other news driving a couple of the stocks higher. BioNTech and its partner, Pfizer, announced a letter of intent with Biovac to produce COVID-19 vaccines for distribution to 55 member countries of the African Union. Moderna announced new supply deals with Japan and Taiwan.\n\nImage source: Getty Images.\nSo what\nAlthough worries about the delta variant primarily fueled the gains for BioNTech, Moderna, and Novavax this week, it remains to be seen what impact the variant will actually have on the companies' fortunes. The CDC and the U.S. Food and Drug Administration (FDA) maintain that current vaccines on the market offer strong protection against severe cases of COVID-19, even ones caused by the delta variant.\nOne study published in the New England Journal of Medicine on Wednesday seemed to back up the CDC-FDA stance for a couple of COVID-19 vaccines. The study found that the Pfizer-BioNTech vaccine and AstraZeneca Plc's vaccine (which hasn't received Emergency Use Authorization in the U.S. yet) are almost as effective against the delta variant as they are against the alpha variant first identified in the U.K. The Pfizer-BioNTech vaccine was 88% effective at preventing symptomatic COVID-19 caused by the delta variant, only a little lower than the vaccine's 93.7% efficacy against the alpha variant.\nHowever, real-world data from Israel announced earlier this month wasn't so encouraging. Israel's Health Ministry stated that the Pfizer-BioNTech vaccine's efficacy fell to 64% from an earlier efficacy of 95.3% when the delta variant wasn't prevalent.\nHow the vaccines fare against the delta variant is important in part because of what it could mean for the need for third booster doses. If booster doses are required, sales for authorized vaccines could be even higher than what is currently projected.\nNow what\nLook for BioNTech (along with Pfizer) and Moderna to keep picking up more deals to supply doses of their COVID-19 vaccines in 2022. Both companies also should continue to build their cash stockpiles and could put the money to use through acquisitions and licensing agreements to bolster their pipelines.\nFor Novavax, the major milestone ahead is the company's anticipated filing for Emergency Use Authorizations (EUAs) for its COVID-19 vaccine in the U.S., U.K., and European Union later this quarter. Novavax has already reported positive results from late-stage studies of its vaccine that should bode well for its chances of winning EUA.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5306362,"gmtCreate":1627044165000,"gmtModify":1663231380948,"authorId":3582403330807441,"author":{"id":3582403330807441,"idStr":"3582403330807441","authorId":3582403330807441,"name":"thuiminn","avatar":"https://static.tigerbbs.com/ab77e304f9cf03ebe236699fa09e54b7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175227861,"type":1,"supId":5305239,"prevId":0,"content":"like and comment","text":"like and comment","html":"like and comment"},{"id":5305210,"gmtCreate":1627036719192,"gmtModify":1663231376635,"authorId":3581740009720756,"author":{"id":3581740009720756,"idStr":"3581740009720756","authorId":3581740009720756,"name":"trashbin","avatar":"https://static.tigerbbs.com/42bc5ae713c40f98d81014f3b0eb7def","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175227861,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5305239,"gmtCreate":1627036856008,"gmtModify":1663231374143,"authorId":3582020670131796,"author":{"id":3582020670131796,"idStr":"3582020670131796","authorId":3582020670131796,"name":"Chibichibi","avatar":"https://static.tigerbbs.com/671a41a5ed2aa68a8f1cfd3e8d82402a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":175227861,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":81,"commentSize":9,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2153198394"}